Safety and Immunogenicity of the ID93 + GLA-SE Tuberculosis Vaccine in BCG-Vaccinated Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial

Safety and Immunogenicity of the ID93 + GLA-SE Tuberculosis Vaccine in BCG-Vaccinated Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial

Abstract Introduction This randomized, double-blind, placebo-controlled, phase 2a trial was conducted to evaluate the safety and immunogenicity of the ID93 + glucopyranosyl lipid adjuvant (GLA)-stable emulsion (SE) vaccine in human immunodeficiency virus (HIV)-negative, previously Bacillus Calmette–...

Full description

Bibliographic Details
Main Authors: Yu Hwa Choi, Young Ae Kang, Kwang Joo Park, Jae Chol Choi, Kwan Goo Cho, Da Yeon Ko, Jun Ho Ahn, Boram Lee, Eunsol Ahn, Yun Ju Woo, Kwangsoo Jung, Nan Yul Kim, Valerie A. Reese, Sasha E. Larsen, Susan L. Baldwin, Steven G. Reed, Rhea N. Coler, Hyejon Lee, Sang-Nae Cho
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-05-01
Series:Infectious Diseases and Therapy
Subjects:
Tuberculosis
Subunit vaccine
GLA-SE
Safety
Immunogenicity
Online Access:https://doi.org/10.1007/s40121-023-00806-0

Internet

https://doi.org/10.1007/s40121-023-00806-0

Similar Items